Five years after the US government began a probe of the generic drug industry, litigation against more than a dozen companies remains in discovery with no trial date on the horizon. But a recent ruling by the judge overseeing the litigation reveals further details on the claims being made against manufacturers.
In a 15 August opinion, Judge Cynthia Rufe, of the US District Court for the Eastern District of Pennsylvania,...







